CLLS earnings call for the period ending September 30, 2020.
News & Analysis: Cellectis
CLLS earnings call for the period ending June 30, 2020.
CLLS earnings call for the period ending March 31, 2020.
CLLS earnings call for the period ending December 31, 2019.
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
Despite getting passed along to a biotech start-up, Cellectis could have a bright future.
Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.
Find out why these stocks missed out on the rally.